Current developments in genomics and personalized health care: Impact on public health

Asia-Pacific Journal of Public Health

Volumn 20, Issue 3, 2008, Pages 242-250

  Manamperi, Aresha ^a  

^a UNIVERSITY OF KELANIYA   (Sri Lanka)

Author keywords

Bioinformatics; Biomarkers; Genomic medicine; Human genome project; Microarrays; Personalized health care

Indexed keywords

ARTICLE; BIOINFORMATICS; GENOMICS; HEALTH CARE SYSTEM; HUMAN; HUMAN GENOME; HUMAN GENOME PROJECT; MEDICAL RESEARCH; MICROARRAY ANALYSIS; SOCIAL ASPECT; TECHNOLOGY;

EID: 45149108032     PISSN: 10105395     EISSN: None     Source Type: Journal    
DOI: 10.1177/1010539508316783     Document Type: Article

References (28)

1. Lander ES, Linton LM, Birren B., et al. Initial sequencing and analysis of the human genome. Nature. 2001 ; 409: 860-921.
2. Venter JC, Adams MD, Myers EW, et al. The sequence of the human genome. Science. 2001 ; 291: 1304-1349.
3. Collins FS, Green ED, Guttmacher AE, Guyer MS A vision for the future of genomic research. Nature. 2003 ; 422: 835-847.
4. Khoury MJ, McCabe LL, McCabe ER Population screening in the age of genomic medicine. N Engl J Med. 2003 ; 348: 50-58.
5. Weinshilboum R. Inheritance and drug response. N Engl J Med. 2003 ; 348: 529-537.
6. Roses AD Pharmacogenetics and practice of medicine. Nature. 2000 ; 405: 857-865.
7. Hoffman SL, Subramanian GM, Collins FH, Venter JC Plasmodium, human and Anopheles genomics and malaria. Nature. 2002 ; 415: 702-709.
8. Jomaa H., Wiesner J., Sanderbrand S., et al. Inhibitors of the nonmevalonate pathway of isoprenoid biosynthesis as antimalarial drugs. Science. 1999 ; 285: 1573-1576.
9. Weintraub LA, Sarwal MM Microarrays: a monitoring tool for transplant patients ? Eur Soc Organ Transplant. 2006 ; 19: 775-788.
10. Livingston DM, Shivdasani R. Towards mechanism-based cancer care. JAMA. 2001 ; 285: 588-593.
11. Schultze JL, Vonderheide RH From cancer genomics to cancer immunotherapy: toward second generation tumor antigens. Trends Immunol. 2001 ; 22: 516-523.
12. Levine AE, Steffen DL orCGDB: a database of genes involved in oral cancer. Nucleic Acids Res. 2001 ; 29: 300-302.
13. Zhu S., Okuno Y., Tsujimoto G., Mamitsuka H. Predicting implicit associated cancer genes from OMIM and MEDLINE by a new probabilistic model. BMC Syst Biol. 2007 ; 1: 15-16.
14. Druker BJ, Lydon NB Lessons learned from the development of ab1 tyrosine kinase inhibitor for chronic myelogenous leukemia. J Clin Invest. 2000 ; 105: 3-7.
15. Schindler T., Bornmann W., Pellicena P., Miller WT, Clarkson B., Kuriyan J. Structural mechanisms for STI-571 inhibition of abelson tyrosine kinase. Science. 2000 ; 289: 1938-1942.
16. Lesage S., Zouali H., Colombel JF, et al. Genetic analyses of chromosome 12 loci in Crohn's disease. Gut. 2000 ; 47: 787-791.
17. Hugot JP, Chamaillard M., Zouali H., et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature. 2001 ; 411: 599-603.
18. Baier LJ, Permana PA, Yang X., et al. A calpain-10 gene polymorphism is associated with reduced muscle mRNA levels and insulin resistance. J Clin Invest. 2000 ; 106: R69 - R73.
19. Horikawa Y., Oda N., Cox NJ, et al. Genetic variation in the gene coding calpain-10 is associated with type 2 diabetes mellitus. Nat Genet. 2000 ; 26: 163-175.
20. Sachidanandam R., Weissman D., Schmidt SC, et al. A map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms. Nature. 2001 ; 409: 928-933.
21. Neamati N., Joseph JB Jr. New paradigms in drug design and discovery. Curr Topics Med Chem. 2002 ; 2: 211-227.
22. Singh S., Malik BK, Sharma DK Molecular drug targets and structure based drug design: a holistic approach. Bioinformation. 2006 ; 1: 314-320.
23. Wlodawer A., Vondrasek J. Inhibitors of HIV-1 protease: a major success of structure-assisted drug design. Annu Rev Biophys Biomol Struct. 1998 ; 27: 249-284.
24. Greer J., Erickson JW, Baldwin JJ, Varney MD Application of the three-dimensional structures of protein target molecules in structure-based drug design. J Med Chem. 1994 ; 37: 1035-1054.
25. Kawakami Y., Inoue A., Kawai T., Wakita M., Sugimoto H., Hopfinger AJ The rationale for E2020 as a potent acetylcholinesterase inhibitor. Bioorg Med Chem. 1996 ; 4: 1429-1446.
26. Burke W., Atkins D., Gwinn M., et al. Genetic test evaluation: information needs for clinicians, policy makers, and the public. Am J Epidemiol. 2002 ; 156: 311-318.
27. Kaye CI, Laxova R., Livingston JE, et al. Integrating genetic services into public health-guidance for state and territorial programs from the National Newborn Screening and Genetics Resource center (NNSGRC). Com Genet. 2001 ; 4: 175-196.
28. Centers for Disease Control and Prevention. Office of Genomics and Disease Prevention. Genomics workforce competencies 2001. http://www.cdc.gov/ genomics/training/competencies/comps.htm. Updated August 14, 2004. Accessed March 12, 2008.